Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology

Le TIAN; Yinghang WANG; Zhi PAN

doi:10.3969/j.issn.1001-5256.2021.03.016

Volume 37 Issue 3

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(3): 582-589

PDF( 5010 KB)

Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology

DOI: 10.3969/j.issn.1001-5256.2021.03.016

Le TIAN¹,
Yinghang WANG²,
Zhi PAN^{1
,
,}

1.
Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun 130117, China
2.
Department of Rheumatism, The Affiliated Hospital of Changchun University of Chinese Medicine, Changchun 130117, China

Received Date: 2020-09-09
Accepted Date: 2020-10-29
Published Date: 2021-03-20

Abstract

Abstract

Objective To investigate the mechanism of Xiaozheng Huoluo prescription (XZHLF) in the prevention and treatment of liver fibrosis based on network pharmacology. Methods TCMSP database, Chemistry Database, ETCM database, chemical source network database, ChemSrc database, and PubChem database were searched and a literature review was performed to collect the chemical components of each traditional Chinese medicine of XZHLF, Swiss ADME database was used to screen out the active components of each traditional Chinese medicine of XZHLF, and Swiss Target Prediction database was used to predict the targets of these active components; GeneCards and OMIN databases were used to collect the disease targets of liver fibrosis, and Venn diagrams were used to obtain the potential targets of XZHLF in the prevention and treatment of liver fibrosis. Cytoscape 3.7.1 software was used to establish a "drug-active component" network for XZHLF and an "active component-potential target" network for XZHLF in the prevention and treatment of liver fibrosis. Metascape database was used to perform GO and KEGG enrichment analysis of potential targets, and bubble charts were plotted for the top 20 pathways with the highest number of enriched genes. The MAPK signaling pathway among the top 20 KEGG pathways was analyzed to plot an "active component-potential target-pathway" network. Healthy Sprague-Dawley rats were randomly divided into blank control group (K group), model group (M group), colchicine-positive control group (Y group), high-dose XZHLF group (G group), middle-dose XZHLF group (Z Group), and low-dose XZHLF group (D group), and a rat model of liver fibrosis was established by CCl₄; the drug was administered simultaneously for 8 weeks. Western blot was used to measure the protein expression of ERK5, p-ERK5, MEK5, and MEKK3 in liver tissue. A one-way analysis of variance was used for comparison of continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups. Results A total of 110 active components were screened out from XZHLF and they acted on 923 targets, which were mapped to 6823 disease targets of liver fibrosis to obtain 647 potential targets. XZHLF might act on multiple protein targets such as EGFR, AKT1, IKBKB, MAPK8, and PDGFRB through the pathways including the MAPK signaling pathway and the biological processes including the regulation of MAPK cascade, thereby playing a role in the prevention and treatment of liver fibrosis. The M group had significant increases in the protein levels of ERK5, p-ERK5, MEK5, and MEKK3 in liver tissue compared with the K, Y, G, Z, and D groups (all P < 0.05), and the K group had significant reductions in the protein levels of ERK5, p-ERK5, MEK5, and MEKK3 in liver tissue compared with the Y, G, Z, and D groups (all P < 0.05). Conclusion Based on the method of network pharmacology, it is predicted that XZHLF may prevent and treat liver fibrosis via the MAPK signaling pathway, and it is verified through experiments that XZHLF prevents and treats liver fibrosis via the ERK5 pathway in the MAPK signaling pathway family. The high-dose XZHLF group shows the most obvious anti-liver fibrosis effect.
- Network Pharmacology,
- Xiaozheng Huoluo Fang,
- Liver Cirrhosis,
- Extracellular-Signal Regulated Kinase 5

FullText(HTML)

References(20)

References

[1]	WEISKIRCHEN R. Hepatoprotective and anti-fibrotic agents: It's time to take the next step[J]. Front Pharmacol, 2015, 6: 303. http://pubmedcentralcanada.ca/pmcc/articles/PMC4703795/
[2]	WYNN TA, RAMALINGAM TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease[J]. Nat Med, 2012, 18(7): 1028-1040. DOI: 10.1038/nm.2807
[3]	SEKI E, BRENNER DA. Recent advancement of molecular mechanisms of liver fibrosis[J]. J Hepatobiliary Pancreat Sci, 2015, 22(7): 512-518. DOI: 10.1002/jhbp.245
[4]	TANG CF. Experimental and clinical study on Xiaozheng Huoluo Fang in prevention and treatment of liver arthralgia[D]. Changchun: Changchun University of Chinese Medicine, 2016. (in Chinese) 唐成芳. 消癥活络方防治肝痹的实验与临床研究[D]. 长春: 长春中医药大学, 2016.
[5]	DAI DX, PAN Z, TANG CF, et al. Effect of Xiaozheng Huoluo Fang on the expression of α-SMA and TGF-β1 in liver tissue of rats with hepatic fibrosis[J]. Jilin J Chin Med, 2017, 37(2): 162-166. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL201702016.htm 代东雪, 潘志, 唐成芳, 等. 消癥活络方对肝纤维化大鼠肝组织α-SMA和TGF-β1表达的影响[J]. 吉林中医药, 2017, 37(2): 162-166. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYJL201702016.htm
[6]	LI S, ZHANG B. Traditional Chinese medicine network pharmacology: Theory, methodology and application[J]. Chin J Nat Med, 2013, 11(2): 110-120. http://europepmc.org/abstract/MED/23787177
[7]	JIN JJ, ZHONG M, YU SM, et al. Therapeutic effect of water extract of chuanposhi on hepatic fibrosis induced by carbon tetrachloride in rats[J]. Chin J Experi Tradi Med Form, 2012, 18(22): 258-262. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201222075.htm 金俊杰, 钟鸣, 余胜民, 等. 穿破石水提取物对四氯化碳致大鼠肝纤维化的治疗作用[J]. 中国实验方剂学杂志, 2012, 18(22): 258-262. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX201222075.htm
[8]	XU SY, BIAN RL, CHEN X. Methodology of pharmacological experiment[M]. 3rd Ed. Beijing: People's Medical Publishing House, 2002: 1350-1351. (in Chinese) 徐淑云, 卞如濂, 陈修. 药理实验方法学[M]. 第3版. 北京: 人民卫生出版社, 2002: 1350-1351.
[9]	LI ZY, TIAN YZ. Tibetan medicine Langqing atta treats liver fibrosis from stasis and heat[J]. J Changchun Univ Tradit Chin Med, 2019, 35(6): 1223-1225. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-CZXX201906062.htm 李忠意, 田耀洲. 藏药郎庆阿塔从瘀热论治肝纤维化[J]. 长春中医药大学学报, 2019, 35(6): 1223-1225. https://www.cnki.com.cn/Article/CJFDTOTAL-CZXX201906062.htm
[10]	YI L, YANG JS. Discussion on TCM pathogenesis of liver fibrosis[J]. J Tradit Chin Med, 2005, 46(11): 806-808. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ200511001.htm 衣蕾, 杨俊生. 肝纤维化中医病机浅探[J]. 中医杂志, 2005, 46(11): 806-808. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZYZ200511001.htm
[11]	HAN B. Treatment of liver fibrosis with traditional Chinese Medicine[J]. Nei Mongol J Tradit Chin Med, 2014, 33(19): 39-40. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-NZYY201419039.htm 韩斌. 浅谈肝纤维化的中医治疗[J]. 内蒙古中医药, 2014, 33(19): 39-40. https://www.cnki.com.cn/Article/CJFDTOTAL-NZYY201419039.htm
[12]	NISHIMOTO S, NISHIDA E. MAPK signalling: ERK5 versus ERK1/2[J]. EMBO Rep, 2006, 7(8): 782-786. DOI: 10.1038/sj.embor.7400755
[13]	CHAO TH, HAYASHI M, TAPPING RI, et al. MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway[J]. J Biol Chem, 1999, 274(51): 36035-36038. DOI: 10.1074/jbc.274.51.36035
[14]	SUN W, KESAVAN K, SCHAEFER BC, et al. MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway[J]. J Biol Chem, 2001, 276(7): 5093-5100. DOI: 10.1074/jbc.M003719200
[15]	ENGLISH JM, VANDERBILT CA, XU S, et al. Isolation of MEK5 and differential expression of alternatively spliced forms[J]. J Biol Chem, 1995, 270(48): 28897-28902. DOI: 10.1074/jbc.270.48.28897
[16]	FANG DJ, LIANG WG, SHEN Y. Recent progress of extracellular signal regulated kinase 5 signal transduction pathway[J]. Guangdong Med J, 2012, 33(1): 140-143. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201201065.htm 方德健, 梁伟国, 沈雁. 细胞外信号调节激酶5信号转导通道研究的最新进展[J]. 广东医学, 2012, 33(1): 140-143. https://www.cnki.com.cn/Article/CJFDTOTAL-GAYX201201065.htm
[17]	WANG Y, SU B, XIA Z. Brain-derived neurotrophic factor activates ERK5 in cortical neurons via a Rap1-MEKK2 signaling cascade[J]. J Biol Chem, 2006, 281(47): 35965-35974. DOI: 10.1074/jbc.M605503200
[18]	DORADO F, VELASCO S, ESPARÍS-OGANDO A, et al. The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation[J]. Nephrol Dial Transplant, 2008, 23(11): 3403-3411. DOI: 10.1093/ndt/gfn333
[19]	RAMSAY AK, MCCRACKEN SR, SOOFI M, et al. ERK5 signalling in prostate cancer promotes an invasive phenotype[J]. Br J Cancer, 2011, 104(4): 664-672. DOI: 10.1038/sj.bjc.6606062
[20]	URUSHIHARA M, TAKAMATSU M, SHIMIZU M, et al. ERK5 activation enhances mesangial cell viability and collagen matrix accumulation in rat progressive glomerulonephritis[J]. Am J Physiol Renal Physiol, 2010, 298(1): F167-F176. DOI: 10.1152/ajprenal.00124.2009

Relative Articles

[1]	Yabo SHI, Yang LI, Huabing LIU, Zhicong WANG, Changwen HUANG. Efficacy and safety of omental wrapping technique for pancreaticojejunal anastomosis in preventing complications after pancreaticoduodenectomy： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(1): 129-137. doi: 10.12449/JCH240122
[2]	Junhao PAN, Jian XIN, Chunhui WANG. Value of preoperative alanine aminotransferase/aspartate aminotransferase combined with multi-phase CT radiological indicators in predicting clinically relevant pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2024, 40(9): 1859-1867. doi: 10.12449/JCH240922
[3]	Jun YU, Chaoyi REN, Wei CUI, Jingxiang SHI. Establishment of a risk prediction model for pancreatic fistula after pancreaticoduodenectomy： A study based on the 2016 edition of the definition and classification system of pancreatic fistula[J]. Journal of Clinical Hepatology, 2024, 40(4): 773-781. doi: 10.12449/JCH240421
[4]	Xin DAI, Hanlin LIU, Qiang WANG, Peng SHU, Long CHENG, Tao WANG. Short-term efficacy and safety of Da Vinci robotic pancreaticoduodenectomy versus traditional laparoscopic pancreaticoduodenectomy: A meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(5): 1106-1113. doi: 10.3969/j.issn.1001-5256.2022.05.025
[5]	Lichen ZHOU, Zhen TAN, Yaping TANG, Zhirong ZHAO, Ruiwu DAI. Value of pancreatic anatomic structure under standard pancreatic neck transection in predicting pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2022, 38(12): 2807-2813. doi: 10.3969/j.issn.1001-5256.2022.12.022
[6]	Lin ZHU, Xiaoli YANG, Li LIU, Lanting XU, Yuanhong LENG, Jing CHEN. Efficacy and safety of enhanced recovery after surgery in the perioperative period of pancreaticoduodenectomy: A systematic review and Meta-analysis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1356-1363. doi: 10.3969/j.issn.1001-5256.2022.06.026
[7]	Li ChangXu, Yuan JingJing, Wang ShouQian, Tang ChaoHui, Xu LuYao, Wang YingChao. Clinical effect of artery-first approach versus traditional approach for pancreaticoduodenectomy:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1805-1810. doi: 10.3969/j.issn.1001-5256.2020.08.025
[8]	Yu PeiHe, Su Song, Chen Shi, Wang JinCheng, Chen XinPei, Luo De. Clinical effect of pancreaticoduodenectomy with total mesopancreas excision versus traditional pancreaticoduodenectomy in treatment of pancreatic head carcinoma and periampullary cancer:A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(8): 1811-1815. doi: 10.3969/j.issn.1001-5256.2020.08.026
[9]	Ji Bo, Liu SongYang, Zhang Wei, Wang YingChao, Liu YaHui. Clinical effect of the enhanced recovery after surgery strategy for pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2019, 35(5): 1032-1036. doi: 10.3969/j.issn.1001-5256.2019.05.019
[10]	Wu YanBin, Zhu HuaMin, Wang XueWen, Niu HongKai, Cheng Yu. Value of real-time elastography in predicting the risk of pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2019, 35(7): 1541-1545. doi: 10.3969/j.issn.1001-5256.2019.07.024
[11]	Zhang BaoHua, Yang Ya, Gong JianPing. Clinical effect and safety of nutritional support after pancreaticoduodenectomy: A Meta-analysis[J]. Journal of Clinical Hepatology, 2018, 34(6): 1231-1236. doi: 10.3969/j.issn.1001-5256.2018.06.020
[12]	Wu Yue, Huang LiPing. Value of real-time shear wave elastography in evaluating classification of liver fibrosis: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(9): 1717-1721. doi: 10.3969/j.issn.1001-5256.2017.09.017
[13]	He XueRong, Zhang BaoHua, Gong JianPing. Effect of preoperative biliary drainage on complications and short-term mortality after pancreaticoduodenectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(9): 1749-1753. doi: 10.3969/j.issn.1001-5256.2017.09.024
[14]	Li WeiNan, Yang Gang, Li JingDong, Tang Tao, Li Qiang, Li Yong. Safety of fast track surgery in pancreaticoduodenectomy: a Meta-analysis[J]. Journal of Clinical Hepatology, 2017, 33(1): 121-125. doi: 10.3969/j.issn.1001-5256.2017.01.026
[15]	Wang XiaoLong, Tu YanYuan, Wang Wei, Yuan ZuRong, Tang JianXiong, Tang WenHao, Wang WeiYi. Risk factors for pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2017, 33(1): 116-120. doi: 10.3969/j.issn.1001-5256.2017.01.025
[16]	Pan Chao, Xi PengCheng, Shi ZuoLiang, Bian JianMin, Yang KunXing, Liu ZiJun, Ni ShaoZhong, Yang ShiYong, Shi KaiWang. Effect of Blumgart anastomosis in prevention and treatment of pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2016, 32(2): 333-336. doi: 10.3969/j.issn.1001-5256.2016.02.028
[17]	Xing GuoQuan, Yan TianQing, Jia ZhiShuo, Kang TieLi. Risk factors for pancreatic fistula after pancreaticoduodenectomy and its prevention and treatment measures [J]. Journal of Clinical Hepatology, 2015, 31(12): 2110-2113. doi: 10.3969/j.issn.1001-5256.2015.12.029
[18]	Yin TianSheng, Yi YaYang, Mao XiXian, Li DeWei. Meta-analysis of risk factors for posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1009-1014. doi: 10.3969/j.issn.1001-5256.2014.10.009
[19]	Pan Fan, Jiang Yi, Zhang XiaoJin, Pan Chen. Risk factors of pancreatic fistula after pancreaticoduodenectomy[J]. Journal of Clinical Hepatology, 2012, 28(8): 587-588+602.
[20]	Li JunJie, Li Xiao, Yue ShuQiang. Analysis of high risks of postoperative pancreaticojejunostomy leakage and its treatment[J]. Journal of Clinical Hepatology, 2011, 27(11): 1213-1218.

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(8)

Get Citation

PDF

XML

Article Metrics

Article views (612) PDF downloads(34)

Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology

DOI: 10.3969/j.issn.1001-5256.2021.03.016

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Mechanism of Xiaozheng Huoluo prescription in preventing liver fibrosis in rats via the ERK5 pathway: An analysis based on network pharmacology

DOI: 10.3969/j.issn.1001-5256.2021.03.016

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content